v3.24.2.u1

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Revenue:
Revenue	$ 2,207	$ 1,081	$ 3,330	$ 2,057
Cost of revenue:
Cost of revenue	2,659	3,074	5,715	6,021
Gross loss	(452)	(1,993)	(2,385)	(3,964)
Operating Expenses:
Research and development	7,631	8,980	15,722	19,119
Sales and marketing	3,655	4,449	7,297	9,002
General and administrative	5,994	5,124	10,368	10,592
Amortization of intangible assets	110	114	224	226
Change in fair value of contingent consideration	5,700	203	12,180	308
Total operating expenses	23,090	18,870	45,791	39,247
Operating loss	(23,542)	(20,863)	(48,176)	(43,211)
Other (expenses) income, net
Change in fair value of warrant liabilities	(1,825)	0	291	0
Interest income	66	431	192	870
Interest expense	(321)	0	(321)	0
Other expense, net	(52)	(242)	(111)	(460)
Total other (expense) income, net	(2,132)	189	51	410
Loss before income taxes	(25,674)	(20,674)	(48,125)	(42,801)
Income tax (expense) benefit	(75)	12	(121)	(79)
Net loss	$ (25,749)	$ (20,662)	$ (48,246)	$ (42,880)
Net loss per common share attributable to common stockholders - basic and diluted (in dollars per share)	$ (0.09)	$ (0.09)	$ (0.18)	$ (0.18)
Weighted average number of shares used in computing net loss per common share - basic and diluted (in shares)	272,316	239,570	270,791	238,929
Comprehensive loss:
Net loss	$ (25,749)	$ (20,662)	$ (48,246)	$ (42,880)
Foreign currency translation (loss) gain	(174)	175	(668)	725
Unrealized gain on available-for-sale investments	1	99	9	406
Comprehensive loss	(25,922)	(20,388)	(48,905)	(41,749)
Product [Member]
Revenue:
Revenue	1,396	298	1,709	591
Cost of revenue:
Cost of revenue	1,155	1,612	2,836	2,837
Service [Member]
Revenue:
Revenue	236	289	521	484
Cost of revenue:
Cost of revenue	695	519	1,147	1,268
Lease [Member]
Revenue:
Revenue	575	494	1,100	982
Cost of revenue:
Cost of revenue	$ 809	$ 943	$ 1,732	$ 1,916

The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (b)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 55
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482640/350-30-55-40

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482665/350-30-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482686/350-30-45-2

ASENSUS SURGICAL, INC. 10-Q